ArticleLaboratory animal research2025
Anti-allergic and anti-inflammatory effects of Gastrodia elata Blume extract in ovalbumin-induced asthma rat model.
Article in Laboratory animal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergic asthma is a chronic inflammatory disease in which bronchial inflammation causes narrowing of the bronchi when exposed to allergens, resulting in coughing, wheezing, and difficulty breathing. Gastrodia elata Blume (GEB) is a perennial Orchidaceae plant native to alpine areas and is known to be effective in anti-inflammatory and anticonvulsants. This study evaluated the anti-inflammatory and anti-allergic effects of GEB extract in a rat model of allergic asthma induced by ovalbumin. This study evaluated the anti-inflammatory and anti-allergic effects of GEB extract in a rat model of allergic asthma induced by ovalbumin. Twenty-four 6-week-old Wistar rats were divided into three groups: control group (CON), ovalbumin (OVA) -induced group, and GEB treatment group. Except for the CON group, the remaining groups were sensitized to OVA by intraperitoneal injection, and asthma was induced by OVA intranasal instillation. The CON and OVA groups were administered distilled water, and the GEB group was administered 7 g/kg of GEB extract for 11 days.
resultsSerum total IgE levels were decreased in the GEB group compared to the OVA group. Also, lung IL-4, IL-5, and IL-13 levels were significantly lower in the GEB group than in the OVA group. Histopathological analysis using hematoxylin and eosin and periodic acid Schiff staining, the tracheal and alveolar walls of the OVA group were thickened, and there was increased infiltration of inflammatory cells in the bronchi, perivascular, and alveolar spaces. As for lung damage caused by OVA, GEB treatment reduced the infiltration of inflammatory cells into the bronchi and blood vessels, and the alveolar spaces were maintained, showing a structure similar to that of the CON group. Immunohistochemical analysis showed that IL-4, IL-5, CD206, and MPO expression levels were reduced in the GEB group compared to the OVA group.
conclusionsThis suggests that GEB treatment has an anti-inflammatory and anti-allergic effect by reducing the levels of IgE and the cytokines IL-4, IL-5, and IL-13 and ameliorating histopathological changes in an asthma rat model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.